8208 Federal Register / Vol. 81, No. 32 / Thursday, February 18, 2016 / Notices 

C. Gastroenterology and Urology 

Devices Panel 

Reviews and evaluates data 

concerning the safety and effectiveness 

of marketed and investigational 

gastroenterology, urology and 

nephrology devices and makes 

appropriate recommendations to the 

Commissioner of Food and Drugs. 

D. General and Plastic Surgery Devices 

Panel 

Reviews and evaluates data 

concerning the safety and effectiveness 

of marketed and investigational general 

and plastic surgery devices and makes 

appropriate recommendations to the 

Commissioner of Food and Drugs. 

E. Hematology and Pathology Devices 

Panel 

Reviews and evaluates data 

concerning the safety and effectiveness 

of marketed and investigational in vitro 

devices for use in clinical laboratory 

medicine including pathology, 

hematology, histopathology, 

cytotechnology and molecular biology 

and makes appropriate 

recommendations to the Commissioner 

of Food and Drugs. 

F. Medical Devices Dispute Resolution 

Provides advice to the Center Director 

on complex or contested scientific 

issues between the FDA and medical 

device sponsors, applicants, or 

manufacturers relating to specific 

products, marketing applications, 

regulatory decisions and actions by 

FDA, and Agency guidance and 

policies. The Panel makes 

recommendations on issues that are 

lacking resolution, are highly complex 

in nature, or result from challenges to 

Agency decisions or actions. 

G. Microbiology Devices Panel 

Reviews and evaluates data 

concerning the safety and effectiveness 

of marketed and investigational in vitro 

devices for use in clinical laboratory 

medicine including microbiology, 

virology, and infectious disease and 

makes appropriate recommendations to 

the Commissioner of Food and Drugs. 

H. Molecular and Clinical Genetics 

Devices Panel 

Reviews and evaluates data 

concerning the safety and effectiveness 

of marketed and investigational in vitro 

devices for use in clinical laboratory 

medicine including clinical and 

molecular genetics and makes 

appropriate recommendations to the 

Commissioner of Food and Drugs. 

I. Neurological Devices Panel 

Reviews and evaluates data 

concerning the safety and effectiveness 

of marketed and investigational devices 

for use in the neurological system and 

makes appropriate recommendations to 

the Commissioner of Food and Drugs. 

J. Orthopaedic and Rehabilitation 

Devices Panel 

Reviews and evaluates data 

concerning the safety and effectiveness 

of marketed and investigational 

orthopedic and rehabilitation devices 

and makes appropriate 

recommendations to the Commissioner 

of Food and Drugs. 

K. Radiological Devices Panel 

Reviews and evaluates data 

concerning the safety and effectiveness 

of marketed and investigational 

diagnostics or therapeutic radiological 

and nuclear medicine devices and 

makes appropriate recommendations to 

the Commissioner of Food and Drugs. 

II. Qualifications 

Persons nominated for the device 

panels should be full-time employees of 

firms that manufacture products that 

would come before the panel, or 

consulting firms that represent 

manufacturers, or have similar 

appropriate ties to industry. 

III. Selection Procedure 

Any industry organization interested 

in participating in the selection of an 

appropriate nonvoting member to 

represent industry interests should send 

a letter stating that interest to the FDA 

contact (see FOR FURTHER INFORMATION

CONTACT) within 30 days of publication 

of this document (see DATES). Within the 

subsequent 30 days, FDA will send a 

letter to each organization that has 

expressed an interest, attaching a 

complete list of all such organizations; 

and a list of all nominees along with 

their current resumes. The letter will 

also state that it is the responsibility of 

the interested organizations to confer 

with one another and to select a 

candidate, within 60 days after the 

receipt of the FDA letter, to serve as the 

nonvoting member to represent industry 

interests for a particular device panel. 

The interested organizations are not 

bound by the list of nominees in 

selecting a candidate. However, if no 

individual is selected within 60 days, 

the Commissioner will select the 

nonvoting member to represent industry 

interests. 

IV. Application Procedure 

Individuals may self nominate and/or 

an organization may nominate one or 

more individuals to serve as a nonvoting 

industry representative. Contact 

information, a current curriculum vitae, 

and the name of the Committee of 

interest may be submitted to the FDA 

Advisory Committee Membership 

Nomination Portal (see ADDRESSES) 

within 30 days of publication of this 

document (see DATES). FDA will forward 

all nominations to the organizations 

expressing interest in participating in 

the selection process for the particular 

device panel. (Persons who nominate 

themselves as nonvoting industry 

representatives will not participate in 

the selection process). 

This notice is issued under the 

Federal Advisory Committee Act (5 

U.S.C. app. 2) and 21 CFR part 14, 

relating to advisory committees. 

Dated: February 11, 2016. 

Jill Hartzler Warner, 

Associate Commissioner for Special Medical 

Programs. 

[FR Doc. 2016–03283 Filed 2–17–16; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

[Document Identifier OS–4040–0005 60D] 

Agency Information Collection 

Activities; Submission to OMB for 

Review and Approval; Public Comment 

Request 

AGENCY: Electronic Government Office, 

HHS. 

ACTION: Notice. 

SUMMARY: In compliance with section 

3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, the Electronic 

Government Office (EGOV), Department 

of Health and Human Services, has 

submitted an Information Collection 

Request (ICR), described below, to the 

Office of Management and Budget 

(OMB) for review and approval. The ICR 

is for a 3-year extension for OMB 

Control Number 4040–0005. The ICR 

will expire on July 31, 2016. The ICR 

also requests categorizing the form as a 

common form, meaning HHS will only 

request approval for its own use of the 

form rather than aggregating the burden 

estimate across all Federal Agencies as 

was done for previous actions on this 

OMB control number. Comments 

submitted during the first public review 

of this ICR will be provided to OMB. 

OMB will accept further comments from 

the public on this ICR during the review 

and approval period. 

DATES: Comments on the ICR must be 

received on or before April 18, 2016. 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 81, No. 32 / Thursday, February 18, 2016 / Notices 8209 

ADDRESSES: Submit your comments to 

ed.calimag@hhs.gov or (202) 690–7569. 

FOR FURTHER INFORMATION CONTACT: 

Information Collection Clearance staff, 

Information.CollectionClearance@

hhs.gov or (202) 690–6162. 

SUPPLEMENTARY INFORMATION: When 

submitting comments or requesting 

information, please include the OMB 

control number 4040–0005. Form is 

available http://www.grants.gov or upon 

request. 

Information Collection Request Title: 

SF–424 Application for Federal 

Assistance—Individual. 

OMB No.: 4040–0005. 

Abstract: The SF–424 Application for 

Federal Assistance—Individual is a 

common form used by Federal grantmaking agencies for individual 

applicants without DUNS numbers to 

apply for Federal financial assistance. 

Need and Proposed Use of the 

Information: The SF–424 Application 

for Federal Assistance—The Individual 

common form is used by individuals not 

associated with organizations to apply 

for Federal financial assistance in the 

form of grants. These forms are 

submitted to the Federal grant-making 

agencies for evaluation and review. 

Likely Respondents: Organizations 

and institutions seeking grants. 

Burden Statement: Burden in this 

context means the time expended by 

persons to generate, maintain, retain, 

disclose or provide the information 

requested. This includes the time 

needed to review instructions, to 

develop, acquire, install and utilize 

technology and systems for the purpose 

of collecting, validating and verifying 

information, processing and 

maintaining information, and disclosing 

and providing information, to train 

personnel and to be able to respond to 

a collection of information, to search 

data sources, to complete and review 

the collection of information, and to 

transmit or otherwise disclose the 

information. The total annual burden 

hours estimated for this ICR are 

summarized in the table below. 

HHS does not use the form; however, 

HHS estimates that the SF–424 

Application for Federal Assistance— 

Individual’s will take 1 hour to 

complete. 

Once OMB approves the use of this 

common form, federal agencies may 

request OMB approval to use this 

common form without having to publish 

notices and request public comments for 

60 and 30 days. Each agency must 

account for the burden associated with 

their use of the common form. 

EGOV specifically requests comments 

on (1) the necessity and utility of the 

proposed information collection for the 

proper performance of the agency’s 

functions, (2) the accuracy of the 

estimated burden, (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected, and (4) the 

use of automated collection techniques 

or other forms of information 

technology to minimize the information 

collection burden. 

TOTAL ESTIMATED ANNUALIZED BURDEN HOURS

Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total 

burden hours 

SF–424 Application for Federal Assistance—Individual .................................. 0 1 1 0 

Total .......................................................................................................... 0 ........................ ........................ 0 

Terry S. Clark, 

Asst Information Collection Clearance 

Officer. 

[FR Doc. 2016–03249 Filed 2–17–16; 8:45 am] 

BILLING CODE 4150–57–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Alcohol Abuse 

and Alcoholism; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Alcohol Abuse and Alcoholism Special 

Emphasis Panel; Multi-Site Randomized 

Controlled Clinical Trial Research Center on 

Alcohol’s Health Effects (U10). 

Date: March 29, 2016. 

Time: 11:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health— 

NIAAA, 5635 Fishers Lane, Conference Room 

2098, Rockville, MD 20892 (Telephone 

Conference Call). 

Contact Person: Ranga Srinivas, Ph.D., 

Chief, Extramural Project Review Branch, 

National Institute on Alcohol Abuse and 

Alcoholism, National Institutes of Health, 

5365 Fishers Lane, Room 2085, Rockville, 

MD 20852, (301) 451–2067, srinivar@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.271, Alcohol Research 

Career Development Awards for Scientists 

and Clinicians; 93.272, Alcohol National 

Research Service Awards for Research 

Training; 93.273, Alcohol Research Programs; 

93.891, Alcohol Research Center Grants; 

93.701, ARRA Related Biomedical Research 

and Research Support Awards, National 

Institutes of Health, HHS) 

Dated: February 11, 2016. 

Melanie J. Gray, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2016–03240 Filed 2–17–16; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

mstockstill on DSK4VPTVN1PROD with NOTICES